FibroGen Inc
NASDAQ:FGEN

Watchlist Manager
FibroGen Inc Logo
FibroGen Inc
NASDAQ:FGEN
Watchlist
Price: 8.38 USD -3.68%
Market Cap: 33.9m USD

Relative Value

The Relative Value of one FGEN stock under the Base Case scenario is hidden USD. Compared to the current market price of 8.38 USD, FibroGen Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FGEN Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
49
vs Industry
84
Median 3Y
1.4
Median 5Y
4.1
Industry
7.9
Forward
5
vs History
4
vs Industry
Median 3Y
-0.8
Median 5Y
-3.9
Industry
23.7
Forward
-1.5
vs History
vs Industry
Median 3Y
-0.6
Median 5Y
-0.9
Industry
22
vs History
vs Industry
Median 3Y
-0.5
Median 5Y
-0.7
Industry
23.8
vs History
vs Industry
Median 3Y
-0.4
Median 5Y
-0.2
Industry
3.3
vs History
vs Industry
63
Median 3Y
0.3
Median 5Y
2.2
Industry
8.3
Forward
-9.5
vs History
vs Industry
54
Median 3Y
0.3
Median 5Y
2.3
Industry
10.1
vs History
0
vs Industry
29
Median 3Y
-0.2
Median 5Y
-1.7
Industry
6.4
Forward
1.2
vs History
0
vs Industry
27
Median 3Y
-0.2
Median 5Y
-1.6
Industry
7
Forward
1.1
vs History
12
vs Industry
32
Median 3Y
-0.1
Median 5Y
-0.6
Industry
8.3
vs History
12
vs Industry
28
Median 3Y
-0.1
Median 5Y
-0.6
Industry
6.5
vs History
vs Industry
64
Median 3Y
0.2
Median 5Y
1.4
Industry
5.7

Multiples Across Competitors

FGEN Competitors Multiples
FibroGen Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
FibroGen Inc
NASDAQ:FGEN
33.9m USD 4.1 0.2 0.5 0.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 809 907.8 -160 693.5 -195 133.1 -192 906.4
US
Abbvie Inc
NYSE:ABBV
394.7B USD 6.6 168.1 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
170.9B USD 4.8 24.4 17.7 17.7
US
Gilead Sciences Inc
NASDAQ:GILD
148.6B USD 5.1 18.3 12.3 12.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
114.8B USD 9.8 31.2 22.9 23.9
US
Epizyme Inc
F:EPE
94.1B EUR 2 083.7 -531.7 -579 -563.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.1B USD 5.5 17.1 16.2 18.4
AU
CSL Ltd
ASX:CSL
86.8B AUD 3.7 19.2 12.9 16.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.4B USD 16.3 1 202.7 158 191.6
NL
argenx SE
XBRU:ARGX
43B EUR 14 33 56.7 58.2
P/S Multiple
Revenue Growth P/S to Growth
US
FibroGen Inc
NASDAQ:FGEN
Average P/S: 3 073 823.8
4.1
-40%
N/A
FR
Pharnext SCA
OTC:PNEXF
33 809 907.8
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.1
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.8
10%
1
US
E
Epizyme Inc
F:EPE
2 083.7
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.5
6%
0.9
AU
CSL Ltd
ASX:CSL
3.7
5%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
16.3
46%
0.4
NL
argenx SE
XBRU:ARGX
14
49%
0.3
P/E Multiple
Earnings Growth PEG
US
FibroGen Inc
NASDAQ:FGEN
Average P/E: 168.2
0.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 693.5 N/A N/A
US
Abbvie Inc
NYSE:ABBV
168.1
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.4
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.3
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.2
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
9%
1.9
AU
CSL Ltd
ASX:CSL
19.2
11%
1.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 202.7
N/A N/A
NL
argenx SE
XBRU:ARGX
33
40%
0.8
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
FibroGen Inc
NASDAQ:FGEN
Average EV/EBITDA: 34.8
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 133.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.7
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.9
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
11%
1.5
AU
CSL Ltd
ASX:CSL
12.9
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
NL
argenx SE
XBRU:ARGX
56.7
839%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
FibroGen Inc
NASDAQ:FGEN
Average EV/EBIT: 40.2
0.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 906.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.7
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.3
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.9
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.5 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18.4
13%
1.4
AU
CSL Ltd
ASX:CSL
16.1
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
191.6
N/A N/A
NL
argenx SE
XBRU:ARGX
58.2
N/A N/A